[1]
Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 2007 Aug:27(8):1687-93
[PubMed PMID: 17556654]
[2]
Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which? Where? When? Arteriosclerosis, thrombosis, and vascular biology. 2009 Dec:29(12):1989-96. doi: 10.1161/ATVBAHA.108.177402. Epub 2009 Jul 10
[PubMed PMID: 19592470]
[3]
Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 2007 Dec:27(12):2507-13
[PubMed PMID: 17916770]
[4]
Marshall AL. Diagnosis, treatment, and prevention of venous thromboembolism in pregnancy. Postgraduate medicine. 2014 Nov:126(7):25-34. doi: 10.3810/pgm.2014.11.2830. Epub
[PubMed PMID: 25387211]
[5]
Antoniou S. Rivaroxaban for the treatment and prevention of thromboembolic disease. The Journal of pharmacy and pharmacology. 2015 Aug:67(8):1119-32. doi: 10.1111/jphp.12387. Epub 2015 Jun 9
[PubMed PMID: 26059702]
[6]
Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. Journal of thrombosis and thrombolysis. 2016 Jan:41(1):206-32. doi: 10.1007/s11239-015-1310-7. Epub
[PubMed PMID: 26780747]
[7]
Barr D, Epps QJ. Direct oral anticoagulants: a review of common medication errors. Journal of thrombosis and thrombolysis. 2019 Jan:47(1):146-154. doi: 10.1007/s11239-018-1752-9. Epub
[PubMed PMID: 30298305]
[8]
Zeballos-Palacios CL, Hargraves IG, Noseworthy PA, Branda ME, Kunneman M, Burnett B, Gionfriddo MR, McLeod CJ, Gorr H, Brito JP, Montori VM, Shared Decision Making for Atrial Fibrillation (SDM4AFib) Trial Investigators. Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice. Mayo Clinic proceedings. 2019 Apr:94(4):686-696. doi: 10.1016/j.mayocp.2018.08.030. Epub 2019 Jan 11
[PubMed PMID: 30642640]
[9]
Giustozzi M, Agnelli G, Quattrocchi S, Acciarresi M, Alberti A, Caso V, Vedovati MC, Venti M, Paciaroni M. Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation. Cerebrovascular diseases extra. 2020:10(2):44-49. doi: 10.1159/000506923. Epub 2020 May 6
[PubMed PMID: 32375143]
[10]
Pachón V, Trujillo-Santos J, Domènech P, Gallardo E, Font C, González-Porras JR, Pérez-Segura P, Maestre A, Mateo J, Muñoz A, Peris ML, Lecumberri R. Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus. TH open : companion journal to thrombosis and haemostasis. 2018 Oct:2(4):e373-e386. doi: 10.1055/s-0038-1675577. Epub 2018 Nov 5
[PubMed PMID: 31249964]
Level 3 (low-level) evidence
[11]
Mulder FI, Di Nisio M, Ay C, Carrier M, Bosch FTM, Segers A, Kraaijpoel N, Grosso MA, Zhang G, Verhamme P, Wang TF, Weitz JI, Middeldorp S, Raskob G, Beenen LFM, Büller HR, van Es N. Clinical implications of incidental venous thromboembolism in cancer patients. The European respiratory journal. 2020 Feb:55(2):. pii: 1901697. doi: 10.1183/13993003.01697-2019. Epub 2020 Feb 6
[PubMed PMID: 31727694]
[12]
Maraveyas A, Muazzam I, Noble S, Bozas G. Advances in managing and preventing thromboembolic disease in cancer patients. Current opinion in supportive and palliative care. 2017 Dec:11(4):347-354. doi: 10.1097/SPC.0000000000000309. Epub
[PubMed PMID: 29068809]
Level 3 (low-level) evidence
[13]
Leow AS, Sia CH, Tan BY, Loh JP. A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus. Journal of thrombosis and thrombolysis. 2018 Jul:46(1):68-73. doi: 10.1007/s11239-018-1656-8. Epub
[PubMed PMID: 29616407]
Level 3 (low-level) evidence
[14]
Paciaroni M, Agnelli G, Caso V, Venti M, Milia P, Silvestrelli G, Parnetti L, Biagini S. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. Journal of thrombosis and haemostasis : JTH. 2005 Jun:3(6):1218-23
[PubMed PMID: 15892862]
Level 2 (mid-level) evidence
[15]
Singh M, Sporn ZA, Schaff HV, Pellikka PA. ACC/AHA Versus ESC Guidelines on Prosthetic Heart Valve Management: JACC Guideline Comparison. Journal of the American College of Cardiology. 2019 Apr 9:73(13):1707-1718. doi: 10.1016/j.jacc.2019.01.038. Epub
[PubMed PMID: 30947924]
[16]
Mejilla A, Guirguis M, Koshman S, Bungard TJ. Venous Thromboembolism Prophylaxis on General Internal Medicine Units: Are Patients Well Served by Current Practice? The Canadian journal of hospital pharmacy. 2017 May-Jun:70(3):200-206
[PubMed PMID: 28680173]
[17]
Donnellan E, Khorana AA. Cancer and Venous Thromboembolic Disease: A Review. The oncologist. 2017 Feb:22(2):199-207. doi: 10.1634/theoncologist.2016-0214. Epub 2017 Feb 7
[PubMed PMID: 28174293]
[18]
Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb:141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303. Epub
[PubMed PMID: 22315270]
Level 1 (high-level) evidence
[19]
Toyoda K. Antithrombotic therapy for pregnant women. Neurologia medico-chirurgica. 2013:53(8):526-30
[PubMed PMID: 23979047]
Level 3 (low-level) evidence
[20]
Lin KJ, Singer DE, Glynn RJ, Blackley S, Zhou L, Liu J, Dube G, Oertel LB, Schneeweiss S. Prediction Score for Anticoagulation Control Quality Among Older Adults. Journal of the American Heart Association. 2017 Oct 5:6(10):. doi: 10.1161/JAHA.117.006814. Epub 2017 Oct 5
[PubMed PMID: 28982676]
Level 2 (mid-level) evidence
[21]
Winter WE, Flax SD, Harris NS. Coagulation Testing in the Core Laboratory. Laboratory medicine. 2017 Nov 8:48(4):295-313. doi: 10.1093/labmed/lmx050. Epub
[PubMed PMID: 29126301]
[22]
Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. The Annals of pharmacotherapy. 2013 May:47(5):714-24. doi: 10.1345/aph.1R634. Epub 2013 Apr 12
[PubMed PMID: 23585642]
Level 3 (low-level) evidence
[23]
Wilson SE, Douketis JD, Crowther MA. Treatment of warfarin-associated coagulopathy: a physician survey. Chest. 2001 Dec:120(6):1972-6
[PubMed PMID: 11742930]
[24]
Su Z, Zhang H, He W, Ma J, Zeng J, Jiang X. Meta-analysis of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in Latin American patients with atrial fibrillation. Medicine. 2020 May:99(18):e19542. doi: 10.1097/MD.0000000000019542. Epub
[PubMed PMID: 32358343]
Level 1 (high-level) evidence
[25]
Rowe AS, Dietrich S, Hamilton LA. Analysis of anticoagulation reversal survey (ARES). Hospital practice (1995). 2020 Aug:48(3):123-127. doi: 10.1080/21548331.2020.1753435. Epub 2020 Apr 15
[PubMed PMID: 32295428]
Level 3 (low-level) evidence
[27]
Maarse M, Swaans MJ, Boersma LVA. Postprocedural Management: Anticoagulation and Beyond. Cardiac electrophysiology clinics. 2020 Mar:12(1):77-88. doi: 10.1016/j.ccep.2019.10.002. Epub 2019 Dec 25
[PubMed PMID: 32067650]
[28]
Bell BR, Spyropoulos AC, Douketis JD. Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. Hematology/oncology clinics of North America. 2016 Oct:30(5):1073-84. doi: 10.1016/j.hoc.2016.05.005. Epub
[PubMed PMID: 27637308]
Level 3 (low-level) evidence
[29]
Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Archives of internal medicine. 2008 Jan 14:168(1):63-9. doi: 10.1001/archinternmed.2007.23. Epub
[PubMed PMID: 18195197]
[30]
Bhalla V, Lamping OF, Abdel-Latif A, Bhalla M, Ziada K, Smyth SS. Contemporary Meta-Analysis of Extended Direct-Acting Oral Anticoagulant Thromboprophylaxis to Prevent Venous Thromboembolism. The American journal of medicine. 2020 Sep:133(9):1074-1081.e8. doi: 10.1016/j.amjmed.2020.01.037. Epub 2020 Mar 6
[PubMed PMID: 32151593]
Level 1 (high-level) evidence
[31]
Ding WY, Harrison S, Gupta D, Lip GYH, Lane DA. Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. Frontiers in medicine. 2020:7():54. doi: 10.3389/fmed.2020.00054. Epub 2020 Feb 21
[PubMed PMID: 32154260]
[32]
Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, Prandoni P, Büller HR, Rodger MA, MARVELOUS Collaborators. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ (Clinical research ed.). 2019 Jul 24:366():l4363. doi: 10.1136/bmj.l4363. Epub 2019 Jul 24
[PubMed PMID: 31340984]
Level 1 (high-level) evidence
[33]
Albertsen IE, Piazza G, Søgaard M, Nielsen PB, Larsen TB. Extended oral anticoagulation after incident venous thromboembolism - a paradigm shift? Expert review of cardiovascular therapy. 2020 Apr:18(4):201-208. doi: 10.1080/14779072.2020.1755260. Epub 2020 Apr 26
[PubMed PMID: 32276561]
[34]
Girbea A, Sprynger M, Moonen M, Lancellotti P. [How Itreat ... extended duration of anticoagulation in lower-limb deep venous thrombosis]. Revue medicale de Liege. 2020 Apr:75(4):203-209
[PubMed PMID: 32267106]